B
Bioheng
A high-tech R&D innovation company
About Bioheng
Bioheng Therapeutics is a clinical-stage company specializing in allogeneic off-the-shelf universal CAR T therapies. The company operates in the biotechnology sector, focusing on innovative cell therapies to address unmet medical needs in autoimmune diseases and oncology. Bioheng's core product is based on its proprietary UCAR T technology platform, ANSWER, which has shown promising safety and efficacy in clinical trials. The company received IND approval for CTA101, the first UCAR T IND in China, and its CD7 targeted UCAR T, CTD40X, received Orphan Drug Designation from the U.S. FDA for treating T-cell acute lymphoblastic leukemia (T-ALL). Bioheng serves patients with severe autoimmune and cancer conditions, aiming to provide effective and accessible treatments. The business model revolves around developing and commercializing its CAR T therapies through clinical trials and regulatory approvals, generating revenue from licensing, partnerships, and eventual product sales. The company is actively progressing its global clinical trials and expanding its pipeline to include multiple UCAR T programs with robust and extended persistence.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Nanjing City, China
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 57.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Innovation Management, Biotechnology, Genetics and genomics, Genome Engineering, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Mar 2021 | $80M | $320M | Shenzhen Capital Group · GL Ventures · Octagon Capital Partners · BlueRun Ventures | — |
| SERIES AOther financing | Feb 2019 | $15M | $59M | Decheng Capital | — |
Growth signals
Latest recorded traffic for Bioheng is 670 monthly website visits, down 15.2% over the last three months. Bioheng's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Decheng Capital
Octagon Capital Partners
Shenzhen Capital Group
GL Ventures
BlueRun Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bioheng on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bioheng’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.